NCT01740323View on ClinicalTrials.gov

Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
Breast Cancer
Interventions
DRUG

Placebo

daily placebo for 6 weeks

DRUG

Curcumin

500 mg BID

Trial Locations (1)

30322

Emory University, Atlanta

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Andrew H Miller

OTHER

NCT01740323 - Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy | Biotech Hunter | Biotech Hunter